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Background/aim: The data concerning the effects of desmopressin on water/electrolyte disturbances of children with primary
monosymptomatic nocturnal enuresis (PMNE) are limited. In the present study we aimed to evaluate the effect and tolerability of
desmopressin on blood and urine electrolytes and osmolality in PMNE.
Materials and methods: Thirty-five children with PMNE between the ages of 5 and 15 participated in the study. Patients collected urine
during the daytime and acknowledged the night time fluid restriction before starting to use the desmopressin tablets. The medication
was taken orally at least 1 h before bedtime. Blood and urine samples were collected before the introduction of the treatment (day 0) and
on the third and seventh days of the administration of desmopressin to determine osmolality and electrolyte levels.
Results: Thirty-five patients participated in the study. Twenty-one patients (60%) were male and 14 (40%) were female. The mean age
was 9.6 ± 2.7 years. There were no significant changes in serum osmolality, urine osmolality, and serum sodium concentration. Mean
urine calcium/creatinine ratio was 0.03 ± 0.01 mg/mg at the beginning, 0.06 ± 0.02 mg/mg on the third day, and 0.04 ± 0.01 mg/mg on
the seventh day of the study. No significant changes were seen in urine calcium/creatinine ratio before and after treatment.
Conclusion: Desmopressin appeared to be a well-tolerated drug and provided a safe and effective treatment for children who were
following fluid intake restriction for PMNE.
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1. Introduction
Nocturnal enuresis (NE) is defined as involuntary leakage
of urine during sleep (1). Intermittent incontinence of urine
in a sleeping child who has previously been dry for less than
6 months without any other lower urinary tract symptoms
is considered to be primary monosymptomatic nocturnal
enuresis (PMNE) (2). The prevalence of enuresis varies
according to age groups. In general, the rate of NE is 15%–
20% around the age of 5, 7% at the age of 10, and 3% at the
age of 12; it is reduced to 1% in subjects aged 15 and older
(3). The etiology of NE is not yet fully elucidated. Multiple
factors may play a role in its etiology. Factors leading to
the pathophysiology of NE are genetic factors, wake up
disorders, night-time low bladder capacity, detrusor
overactivity, and nocturnal polyuria (4). According to the
2002 International Continence Society definition, nocturia
is defined as waking at night to void and production of
an abnormally large volume of urine during sleep (5).
Electrolyte disturbances also may cause NE. Pace et al. (6)
showed that hypercalciuria, especially the absorptive type,
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may lead to NE. Disturbances of secretion of antidiuretic
hormone (ADH) is another factor causing NE (7,8). The
majority of the children with monosymptomatic nocturnal
enuresis do not show a normal circadian rhythm of the
ADH arginine vasopressin (AVP). i.e. the expected
increase of vasopressin is not observed in them (8). Rittig
et al. (9) showed that vasopressin has a diurnal rhythm of
constant levels during the day (0800–2200 hours) and a
highly significant increase during the night (2200–0800
hours) in normal subjects. In contrast, enuretics showed
a significantly less pronounced nocturnal increase in
vasopressin with significantly lower nocturnal levels
than normal subjects. Normal subjects showed a diurnal
rhythm in urinary excretion rate reciprocal to urinary
osmolality with a low and highly concentrated nocturnal
urinary output. In enuretics, however, this normal diurnal
rhythm was absent.
Different treatment methods such as medical
treatments (imipramine, desmopressin, anticholinergics),
behavioral interventions, and enuresis alarm therapy are
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used in cases of NE (10). Desmopressin is a synthetic
analog of arginine vasopressin that has an antidiuretic
effect and reduces the production of urine and increases
the urine concentration. The half-life of desmopressin
is 1.5–3 h. An increasing number of reports show that
administration of desmopressin seems to improve
nocturia (11). Desmopressin is involved in management
of primary nocturnal enuresis according to guidelines
that have been developed by the International Children’s
Continence Society, the National Institute for Health
and Care Excellence, and the Paediatric Society of New
Zealand (12). Desmopressin is produced in tablet, melt,
and nasal spray forms. Since the sublingual melt form of
desmopressin melts readily, it is efficient and easy to use.
The recommended melt dose is 120–240 µg (maximum:
360 µg). The risk of side effects is very low in patients with
night time fluid restriction. The risk of water intoxication
and hyponatremia can be prevented by limiting
fluid intake. Due to its prolonged duration of action,
occasionally desmopressin may lead to hyponatremia by
blocking the mechanism of compensatory diuresis (13).
The most serious side effects associated with hyponatremia
are cerebral edema and convulsion. Headache and nausea
in nasal applications and epistaxis, nasal congestion, and
rhinitis can also be added to its side effects (14). However,
data on the effects of desmopressin on water/electrolyte
disturbances in children with PMNE are limited. There are
few studies about its unfavorable side effects and safety of
application. Although its effects are well recognized, the
possible side effects still constitute an important source of
risk.
In the present prospective study we aimed to evaluate
the effect and tolerability of desmopressin on blood and
urine electrolytes and osmolality in PMNE.
2. Materials and methods
Patients attending the pediatric nephrology unit with
the complaint of enuresis were the participants of this
prospective study. The study protocol was approved by the
local ethics committee and informed consent was obtained
from the parents of all patients prior to the beginning of
the study. At the first visit, information on the patient’s
medical history and voiding diaries were collected, and
physical examinations concerning liver and renal function
tests were performed. Based on clinical indications,
laboratory and imaging studies were completed.
Children with PMNE between the ages of 5 and 15
years were included in the prospective study. The physical
examinations of these patients were normal. None of
these patients had hypertension or renal dysfunction.
They did not have any symptoms of neurological or
urological diseases. They also did not have any diurnal
symptoms. Desmopressin melt antidiuretic hormone at

120 µg was prescribed. To obtain optimum antidiuresis
during sleep the medication was applied by mouth to the
subjects at least 1 h before bedtime. We gave directions to
the subjects about limiting excessive water consumption
after dinner and they were limited to fluid intake of 200–
300 mL according to their weight after 2100 hours until
morning. We also informed the patients about the side
effects including headache, vomiting, dizziness, edema,
hyponatremia, and seizures that might occur during
the study. These patients were diagnosed with primary
nocturnal enuresis for the first time and they had not
received any drug treatment before. The exclusion criteria
were patients with daytime enuresis, age of less than 5
and greater than 18, and having symptoms of secondary
enuresis (urination dysfunction, urinary tract infection,
urethral obstruction, ectopic ureter, obstructive sleep
apnea, diabetes mellitus or insipidus, hyperthyroidism).
The patients were asked to collect daytime urine and were
informed about the night time fluid restriction before
starting to take the desmopressin melt tablets. Between
0800 and 0900 hours, blood and urine samples were
collected before the introduction of the treatment (day 0)
and on the third and seventh days of the administration
of desmopressin to determine osmolality and electrolyte
levels. The study subjects were not allowed to eat or drink
prior to the blood and urine sample collections on days 3
and 7.
We used SPSS 11.5 for Windows for the statistical
analysis. The Shapiro–Wilk test was used to investigate
whether the distribution of the continuous variables was
close to normal distribution. Differences between the
means of continuous variables in two and three groups
were evaluated by using Student’s t-test or the Mann–
Whitney U test and the Kruskal–Wallis test or ANOVA
test, respectively, where applicable. Descriptive statistics
for continuous variables are shown as mean ± standard
deviation, and for nominal variables they are shown as
the number of cases and as (%). Repeating measures were
investigated with variance analysis. P < 0.05 was considered
to indicate statistical significance. Serum sodium levels
between 135 and 145 mmol/L were considered normal, and
levels under 135 mmol/L were defined as hyponatremia.
3. Results
In total 35 patients (21 males, 14 females) participated
in this study. The mean age was 9.6 ± 2.7 years. Sixteen
patients were prepubertal and 19 were postpubertal. Daily
liquid intake and urine volume were 1635 ± 734 mL/m2
and 1270 ± 607 mL/m2, respectively (Table 1). There was
no significant difference in blood sodium, potassium, and
osmolality between prepubertal and postpubertal children
(P = 0.552). Blood sodium values were 137.0 ± 1.85 mEq/L
before the treatment and 138.0 ± 2.07 mEq/L and 137.0 ±

1329

TAŞ et al. / Turk J Med Sci
Table 1. Demographic characteristics of the patients.
Variables

Total
n = 35

Prepubertal
n = 16

Postpubertal
n = 19

Age, years

9.6 ± 2.7

7.5 ± 1.4

11.3 ± 1.5

Range of age, years

5.5–16

5.5–9.5

10–16

Males, n (%)

21 (60%)

13 (81.25%)

8 (42%)

Females, n (%)

14 (40.0%)

3 (18.75%)

11 (58%)

Daily liquid intake, mL/m2*

1635 ± 734

1480 ± 694

1740 ± 730

Daily urination, mL/m *

1270 ± 607

1125 ± 551

1383 ± 589

2

*Mean ± SD.

1.95 mEq/L on the third and seventh days of treatment,
respectively. Blood osmolality values were 254.9 ± 20.15
mOsm/kg H2O at the beginning and 260.5 ± 23.9 mOsm/
kg H2O and 260.4 ± 24.47 mOsm/kg H2O on the third and
seventh days of the study, respectively (Table 2). Urine
calcium/creatinine values were 0.03 ± 0.01 mg/mg at
the beginning, 0.06 ± 0.02 mg/mg on the third day, and
0.04 ± 0.01 mg/mg on the seventh day of the study. There
were no significant changes of serum sodium level, serum
osmolality, urine osmolality, or urine calcium/creatinine
ratio (P = 0.618, P = 0.135, P = 0.088, and P = 0.423
respectively). No significant changes were seen in urine
potassium level between the beginning and the seventh
day of the study (P = 0.448) (Table 2). Two weeks after
the initiation of treatment, effects of the medication were
observed. In the follow-up period, the NE complaints of
80% (n = 28) of the patients had been successfully treated

with desmopressin melt tablets. None of the patients had
symptomatic side effects of headache, vomiting, dizziness,
edema, or fatigue.
4. Discussion
The objectives of this study were to investigate the effect
and tolerability of desmopressin on blood and urine
electrolytes and osmolality in PMNE. In this sense, NE
is an important public health problem for children and
parents that affects the quality of life (15). Nocturnal
polyuria (NP) and increased amount of urine during night
time play a role in the pathophysiology of NE (4). NP
may be caused by the disorder of the diurnal rhythm of
secretion of ADH. NP is linked to decreased secretion of
AVP (16–20). This is the basis of desmopressin response
to treatment (7,8). AVP becomes effective on serum
osmolality via V2 receptors. Aquaporin water channels of

Table 2. Serum and urine biochemical values at the beginning and after treatment on the 3rd and 7th days.
Variables*

Day 0

Day 3

Day 7

P-value

Serum calcium (mg/dL)

9.8 ± 0.34

9.8 ± 0.28

9.8 ± 0.33

0.941

Serum sodium (mEq/L)

137.0 ± 1.85

138.0 ± 2.07

137.0 ± 1.95

0.618

Serum potassium (mEq/L)

4.4 ± 0.43

4.3 ± 0.39

4.3 ± 0.46

0.631

Serum osmolarity (mOsm/kg H2O)

254.9 ± 20.15

260.5 ± 23.9

260.4 ± 24.47

0.135

Urine sodium (mEq/L)

143.0 ± 51.95

154.5 ± 55.85

154.7 ± 79.93

0.714

Urine potassium (mEq/L)

67.2 ± 40.65

67.9 ± 39.38

79.1 ± 30.25

0.448

Urine osmolarity (mOsm/kg H2O)

673.6 ± 244.4

798.3 ± 198.3

807.7 ± 198.1

0.088

Urine calcium (mg/dL)

4.5 ± 2.5

7.1 ± 3.1

6.1 ± 2.7

0.135

Urine creatinine (mg/dL)

121.6 ± 20.2

102.9 ± 16.4

122.2 ± 22.4

0.939

Urine calcium (mg)/creatinine (mg)

0.03 ± 0.01

0.06 ± 0.02

0.04 ± 0.01

0.423

Mean ± SD.
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the kidney present in epithelial cells of collecting ducts of
type 2 are stimulated with the desmopressin V2 receptor
and eventually provide water retention (21).
Desmopressin, a synthetic analog of AVP, treats enuresis
by leveling the renal ion and water transport (7). Orally
disintegrating tablets containing desmopressin (MINIRIN
® Melt, Ferring Pharmaceuticals, Saint-Prex, Switzerland),
which are applied sublingually without water, have been
available since 2005 and were recently approved for the
treatment of nocturia in 57 countries (22). MINIRIN
Melt is available in formulations of 60 µg, 120 µg, and
240 µg in Turkey. Vande Walle (23) et al. showed that to
control diuresis for 7–11 h, which is a period similar to the
sleeping time for children, 120 µg is better than the 60 µg
form. Therefore, we prescribe the 120 µg oral form.
One of the most important side effects that may
occur after desmopressin treatment is the antidiuretic
effect caused by water retention and hyponatremia.
Rembratt et al. carried out a metaanalysis study on 632
adult patients and among them 31 patients showed
symptoms of hyponatremia, headache, nausea, vomiting,
fatigue, dizziness, ataxia, and weight loss (24) due to
urine osmolality increase after the administration of an
antidiuretic hormone analog. Moreover, in other adult
studies, there was also a significant change in the sodium
levels (25,26). In our study, no significant hyponatremia
developed in patients that received desmopressin
treatment.
A placebo-controlled study by Rushton et al. (27)
showed that there was an increase in urine osmolality in
the desmopressin responsive group while there was no
difference in the daily urinary osmolality. However, in our
study, urinary osmolality did not change significantly after

the desmopressin treatment. This could be related to the
low number of patients.
Desmopressin treatment provides the regulation of ion
and water transport (28). Chang et al. (25) and Kang et al.
(26) showed that calcium excretion was increased in adult
patients who used desmopressin. In our study, slightly
increased urinary calcium excretion was determined,
but it was not significant. Desmopressin may reduce the
excretion of potassium by affecting the potassium Kir 1.1
channels located in the descending limb of Henle (29).
However, in our study, there was no effect of desmopressin
on potassium.
For ethical reasons, examining the effects of this agent
in healthy children is not possible, so there was no control
group in this study.
In our study, we found that urinary osmolality did not
change significantly during the first days (days 3 and 7)
of the treatment. In this short-term study of treatment
of nocturia with antidiuretic hormone analogs, we
observed no clinically significant adverse events caused
by hyponatremia. It appears that this therapy can be safely
used to treat nocturia patients. Unfortunately the number
of patients (n = 35) and the follow-up period for blood
and urine analysis (7 days) was limited. Therefore, to reach
more reliable conclusions, there is a need for new studies
including more patients and follow-up for longer periods.
In this respect, for the long-term effect of desmopressin in
these patients, prospective extension studies are needed.
Desmopressin appeared to be a well-tolerated drug
and provided safe and effective treatment for children
who were following fluid intake restriction proposals for
PMNE.
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